These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 31277676)

  • 1. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
    Zhang H; Dong S; Feng J
    J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
    Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
    Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias.
    Fang H; Liu J; Guo D; Liu P; Zhao Y
    Chin Med J (Engl); 2014; 127(9):1645-50. PubMed ID: 24791868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
    Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
    J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation.
    Fujii S; Yamashita S; Yamaguchi T; Takahashi M; Hozumi Y; Ushijima T; Mukai H
    Oncotarget; 2017 Mar; 8(12):19039-19048. PubMed ID: 28186977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
    Kang S; Dong SM; Park NH
    Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
    Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
    Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
    Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
    J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.